Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial
Jia Liu(China Academy of Chinese Medical Sciences), Luqi Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jinliang Yang(University of California, Davis), Yongjun Bian(Chinese Academy of Medical Sciences & Peking Union Medical College), Huaxin Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wensheng Qi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ming Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Suping Chen(Guangdong University of Technology), Wei Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenliang Lv(Chinese Academy of Medical Sciences & Peking Union Medical College), Luxing Leng(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Haoning Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunyan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhixu Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongyue Xian(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaheng Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ryan Zhenqi Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Lianguo Ruan(Huazhong University of Science and Technology), Bei Yan(Ningxia Medical University), Yue Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Li(Air Force General Hospital PLA), Gang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Li(State Key Laboratory of Respiratory Disease), Dongxu Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Wang(Central South University), Yingying Chen, Li Zhang(Huazhong University of Science and Technology), Xiaodong Cong(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Guo(Shanghai Tenth People's Hospital), Qing Miao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Chen(Science for Life Laboratory), Jianxin Jiang(Lishui City People's Hospital), Xin Shen(Chinese Academy of Medical Sciences & Peking Union Medical College), Lanping Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Chen Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Guoju Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheng Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Lijie Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaolei Xie(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 71
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
|Military Medical Research|2020|2.4k
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Targeting PI3K/Akt signal transduction for cancer therapy
|Signal Transduction and Targeted Therapy|2021|1.7k